CXCL12 and familial pancreatic carcinoma: PSC-derived CXCL12, deoxycytidine, and fibronectin were reported to promote drug resistance in pancreatic cancer; however, the underlying mechanism remains unclear (Amrutkar et al., 2019; Dalin et al., 2019; Singh et al., 2010).